semaglutide victoza Victoza: The First Generic GLP-1 Receptor Agonist Victoza vs Ozempic: Cost &

Here are the key benefits of incorporating this innovative product

Submissions for type 2 diabetes will follow in 2027

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA 1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

On 6 January 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) licensed the new dosage of Wegovy, which is three times higher than the previously available 2.4mg dose for weight loss

With athletes curious about taking them, it's such a nuanced conversation. Sometimes an athlete has been doing everything righttraining, sleeping, eatingand cant seem to unlock that next level